Pfizer raises full-year 2026 revenue guidance to $62 billion to $64 billion

Pfizer reported third-quarter 2026 results on November 3, 2026, and raised its full-year 2026 guidance for revenues and adjusted diluted EPS. Third-quarter GAAP diluted EPS was $0.56, and adjusted diluted EPS was $0.87.

Third-quarter revenues were $16.6 billion, a decrease of $71 million, or relatively flat, compared with the prior-year quarter. Excluding contributions from Comirnaty and Paxlovid, revenues grew 7% on an operational basis. Revenues of the company's launched and acquired products grew 32% on an operational basis.

Pfizer said it now expects 2026 revenues of $62 billion to $64 billion, up $1.5 billion at the midpoint from $60.5 billion to $62.5 billion previously. It said adjusted diluted EPS is now expected to be $2.95 to $3.05, narrowed from $2.80 to $3.00.

Pfizer said its guidance includes a one-time $650 million acquired in-process R&D charge tied to the in-licensing and collaboration agreement with Innovent Biologics, Inc., recorded in the third quarter, with an unfavorable impact of approximately $0.10 per share. Pfizer also said its guidance does not assume completion of any business development transactions not completed as of November 3, 2026, and assumes no share repurchases in 2026.

Pfizer said it anticipates an unfavorable revenue impact of approximately $1.1 billion from recent and expected generic and biosimilar competition. Cecile Guegan was appointed Chief Financial Officer, Executive Vice President, effective November 1, 2026.